SKU PT141 Category

PT141 Bremelanotide is a peptide that researchers use to study central melanocortin pathways. Scientists value this compound because it acts as a selective melanocortin receptor agonist with strong activity in the brain. Although it shares structural similarities with Melanotan II, the PT-141 peptide behaves very differently. It works through central neural pathways rather than peripheral pigmentation mechanisms. Because of this distinction, it allows researchers to investigate CNS-driven signaling with far greater precision.

This product is currently out of stock and unavailable.

The PT141 Bremelanotide peptide supports studies on neuropeptide communication, sexual-behavior research models, and melanocortin-linked neurological responses. It also helps researchers map how specific melanocortin receptors influence arousal pathways, reward systems, and central autonomic processes. Since PT-141 interacts primarily with MC3R and MC4R in the brain, scientists often use it to explore the role of melanocortin receptors in behavior, motivation, and neural regulation.

Researchers often buy the PT141 Bremelanotide peptide for work involving:

  • Central melanocortin receptor activation

  • Behavioral and neuroendocrine research models

  • CNS-mediated signaling and intracellular response mapping

  • Comparisons between central and peripheral melanocortin pathways

Because PT141 Bremelanotide produces clear central responses, it gives research teams reliable timing, strong receptor selectivity, and consistent experimental conditions. These qualities make it suitable for controlled brain-pathway investigations, mechanistic receptor studies, and neurobiological experiments that require precise stimulation.

Our PT141 Bremelanotide peptide arrives as a high-purity laboratory reagent intended for qualified research environments only. It serves scientific studies, not medical or diagnostic use.

For research use only. Not for human consumption.

COA Request

GET 10% OFF

Recieve product and research updates through our newsletter